Interactive Savings Map - Find out how much your state saved from generic and biosimilar medicines.
Learn More
Close
  • Fireside chat with Mark Cuban at Access! 2023
    "You guys make such a huge difference that you don't get credit for."
    Mark Cuban on generic medicines.
    View Video
  • Access! 2023 - AAM Annual Meeting
    ICYMI: See What Happened at Access! 2023
    Follow updates on social media with hashtag #Access2023.
    Follow AAM on Twitter
  • AAM's Prescription for State Savings
    AAM’s Prescription for State Savings
    State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.
    Learn More
  • 2021 Savings for Patients by Condition
    Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. Learn more and download fact sheets about the savings by common patient conditions.
    Read Blog
  • AAM 2022 U.S. Generic and Biosimilar Medicines Savings Report
    2022 U.S. Generic & Biosimilar Medicines Savings Report
    Savings continue to grow with $373B saved in 2021 the U.S. health care system, including patients, employers, and taxpayers. With 91% of Rx filled and only 18% of Rx drug spending, findings reinforce the critical importance of the generic and biosimilar industry to America’s patients.
    View Report
  • Study Finds Middlemen Increasingly Block Patient Access to New Generics
    New report shows that middlemen like health plans and pharmacy benefit managers (PBMs) increasingly block patient access, delaying coverage of new generics in favor of higher-priced brand drugs with high rebates.
    Read Press Release
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.
    View Report
  • Markup Madness
    Who’s Profiting from Your Prescription?
    Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.
    Learn More

Working to leave a positive impact on...

Industry Industry We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More
People People We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More
Policy Policy We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Who We Are

Recent Updates

Our Brands and Campaigns

Association for Accessible Medicines

601 New Jersey Ave NW, Suite 850
Washington DC 20001

 

202.249.7100
info@accessiblemeds.org

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.